Androgen Receptor Variant 7 (AR-V7) Transcript Expression in Circulating Tumor Cells.

Tanzila Khan, Yafeng Ma, Alison Luk, Francis Young, Paul de Souza, Wei Chua, Bavanthi Balakrishnar, Therese M Becker

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tanzila KhanIngham Institute Applied and Medical Research, Liverpool, NSW, Australia. tanzila.khan@inghaminstitute.org.au.

Yafeng MaIngham Institute Applied and Medical Research, Liverpool, NSW, Australia.

Alison LukWard 6, Sydney, NSW, Australia.

Francis YoungPrince of Wales Hospital, Sydney, NSW, Australia.

Paul de SouzaSchool of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.

Wei ChuaLiverpool Hospital, Liverpool, NSW, Australia.

Bavanthi BalakrishnarLiverpool Hospital, Liverpool, NSW, Australia.

Therese M BeckerIngham Institute Applied and Medical Research, Liverpool, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, there has been increasing interest in developing drugs that increase the precision targeting of molecular alterations in prostate cancer cells. Traditionally, tissue samples are used to screen for and study such alterations, but liquid biopsies emerge as very practical and potentially superior methodologies to longitudinally characterize cancer cell biology and evolution. The expression of androgen receptor variants correlates with the development of castrate resistance prostate cancer (CRPC), and the most studied variant 7 (AR-V7) is associated with CRPC, disease progression, and resistance to certain AR-pathway targeted treatments and is readily detectable in circulating tumor cells (CTCs). Here, we describe a method of AR-V7 detection in CTCs using highly sensitive droplet digital PCR (ddPCR).

Indexed as

Neoplastic Cells, CirculatingProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenBiomarkers, TumorCell Line, TumorGene Expression Regulation, NeoplasticHumansMalePolymerase Chain ReactionAR protein, humanBiomarkers, TumorReceptors, Androgenandrogen receptor (AR)Androgen receptor variant 7 (AR-V7)Circulating tumor cell (CTC)Droplet digital PCR (ddPCR)Prostate cancer

Identifiers

PMID42426450

DOI10.3389/fonc.2012.00131

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.